Vimarsana
Biggest News Aggregation in the World

Page 32 - Epic Research News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Epic Research. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Epic Research Today - Breaking & Trending Today

GLP-1s Like Semaglutide: Less Thyroid Cancer Than Insulin - Vimarsana News

GLP-1s Like Semaglutide: Less Thyroid Cancer Than Insulin

Among people with type 2 diabetes who received a GLP-1 receptor agonist, there was less correlation between this treatment and thyroid cancer than among people with type 2 diabetes treated with insulin.

Opinion: Why we need tighter regulations for weight loss drugs - Vimarsana News

Opinion: Why we need tighter regulations for weight loss drugs

With a recent study highlighting the potential side effects of weight loss drugs, health agencies should tighten regulations to ensure that only those who need these drugs for health reasons can access them, writes Dr. Simon C. Cork.

Source: yahoo.com
Healthcare Authority Newsletter - September 2023 #3 | Arnall Golden Gregory LLP - Vimarsana News

Healthcare Authority Newsletter - September 2023 #3 | Arnall Golden Gregory LLP

News Briefs - Government Shutdown Could Greatly Impact Health Programs - The threat of a government shutdown is hanging over Capitol Hill, but so is the realization that gridlock could...

CNN Exclusive: Prescriptions for popular diabetes and weight-loss drugs soared, but access is limited for some patients - Vimarsana News

CNN Exclusive: Prescriptions for popular diabetes and weight-loss drugs soared, but access is limited for some patients

(CNN) — As prescriptions for Ozempic soar, the drug and others like it are still reaching only a fraction of the population who could benefit from taking them — and

Source: wevv.com
Prescriptions for popular diabetes and weight-loss drugs soared, but access is limited for some patients - Vimarsana News

Prescriptions for popular diabetes and weight-loss drugs soared, but access is limited for some patients

As prescriptions for Ozempic soar, the drug and others like it are still reaching only a fraction of the population who could benefit from taking them — and the limited supply is disproportionately reaching White patients.

Source: cnn.com